Description: Learn about TRODELVY® (sacituzumab govitecan-hziy) in pretreated HR+/HER2- metastatic breast cancer. See full Prescribing Information, including BOXED WARNING
For the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- (IHC 0, IHC 1+ , or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting
See more data and study design below
In the Phase 3 TROPiCS-02 trial, TRODELVY demonstrated 3.2 more months of overall survival than single-agent chemotherapy (14.4 versus 11.2 months mOS [ P =0.02]; and 5.5 versus 4.0 months mPFS [primary endpoint] [ P =0.0003]; n=272 versus n=271, respectively) 1,2